Skip to main content
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · PHAT ISIN · US71722W1071 US Manufacturing
Filings indexed 458 across all filing types
Latest filing 2026-01-08 Regulatory Filings
Country US United States of America
Listing US PHAT

About Phathom Pharmaceuticals, Inc.

https://www.phathompharma.com/

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for acid-related gastrointestinal (GI) diseases. The company's primary efforts are centered on advancing its lead product candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB). This therapeutic is developed for a range of indications, including the treatment of erosive esophagitis, Helicobacter pylori (H. pylori) infection, and non-erosive reflux disease. Phathom aims to transform the treatment landscape for these conditions by addressing unmet medical needs and improving patient outcomes with innovative therapeutic options.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-01-08 English
424B5
Prospectus
2026-01-08 English
424B5
Prospectus
2026-01-07 English
8-K
Regulatory Filings
2026-01-07 English
S-3ASR
Registration Form
2026-01-07 English
4
Director's Dealing
2026-01-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.